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Abstract
Background: The overall objective of this study was to develop a nanoparticle formulation for dual modality
imaging of head and neck cancer. Here, we report the synthesis and characterization of polymeric phospholipid-
based nanomicelles encapsulating near-infrared (NIR) phosphorescent molecules of Pt(II)-
tetraphenyltetranaphthoporphyrin [Pt(TPNP)] and surface functionalized with gadolinium [Pt(TPNP)-Gd] for
combined magnetic resonance imaging (MRI) and NIR optical imaging applications.
Methods: Dynamic light scattering, electron microscopy, optical spectroscopy and MR relaxometric measurements
were performed to characterize the optical and magnetic properties of nanoparticles in vitro. Subsequently, in vivo
imaging experiments were carried out using nude mice bearing primary patient tumor-derived human head and
neck squamous cell carcinoma xenografts.
Results: The nanomicelles were ~100 nm in size and stable in aqueous suspension. T1-weighted MRI and
relaxation rate (R1 = 1/T1) measurements carried out at 4.7 T revealed enhancement in the tumor immediately
post injection with nanomicelles, particularly in the tumor periphery which persisted up to 24 hours post
administration. Maximum intensity projections (MIPs) generated from 3D T1-weighted images also demonstrated
visible enhancement in contrast within the tumor, liver and blood vessels. NIR optical imaging performed (in vivo
and ex vivo) following completion of MRI at the 24 h time point confirmed tumor localization of the nanoparticles.
The large spectral separation between the Pt(TPNP) absorption (~700 nm) and phosphorescence emission (~900
nm) provided a dramatic decrease in the level of background, resulting in high contrast optical (NIR
phosphorescence) imaging.
Conclusions: In conclusion, Pt(TPNP)-Gd nanomicelles exhibit a high degree of tumor-avidity and favorable
imaging properties that allow for combined MR and optical imaging of head and neck tumors. Further
investigation into the potential of Pt(TPNP)-Gd nanomicelles for combined imaging and therapy of cancer is
currently underway.
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Head and neck squamous cell carcinomas (HNSCC)
constitute a biologically diverse group of neoplasms that
vary in their clinical presentation and therapeutic
response [1,2]. Diagnostic evaluation of head and neck
tumors often involves the useo fn o n - i n v a s i v ei m a g i n g
techniques such as computed tomography (CT), mag-
netic resonance imaging (MRI) and positron emission
tomography (PET). However, currently available
advanced imaging modalities vary in their limits of sen-
sitivity, resolution and depth profiling. Development of
agents that allow imaging of tumors across multiple
platforms could be potentially beneficial for diagnostic
and therapeutic evaluation of cancer in patients.
In this regard, nanoparticle-based platforms have sev-
eral distinct advantages that could potentially allow inte-
gration of diagnostic and therapeutic applications in
oncology [3-5]. First, the ability to incorporate multiple
imaging tracers permits concurrent evaluation of the
same nanoformulation acrossi m a g i n gp l a t f o r m s[ 3 ] .
Secondly, nanoparticles exploit tumor physiological
characteristics such as the enhanced permeability and
retention (EPR) effect, which enables ‘passive targeting’
to tumor sites [4]. Thirdly, nanoplatforms offer a trace-
able chassis onto which specific targeting moieties (anti-
bodies, peptides) can be added according to the desired
biological application [5]. Finally, nanoparticles can be
used as carriers to selectively deliver high doses of mul-
tiple therapeutic agents to cancer sites while minimizing
delivery to normal tissues [4,5].
The overall goal of this study was to develop a nano-
particle-based platform for multimodal imaging of head
and neck cancer. To achieve this goal, we have devel-
oped a phospholipid-based phosphorescent nanomicelle
formulation functionalized with gadolinium for com-
bined magnetic resonance imaging (MRI) and optical
(near-infrared phosphorescence) imaging of tumors.
While the two imaging techniques vary in their resolu-
tion, sensitivity and cost of application, it was our
hypothesis that development of a contrast agent for
both techniques would provide complementary informa-
tion and enable cross-validation of findings. Here, we
report the synthesis and characterization of polymeric
phospholipid nanomicelles encapsulating a NIR phos-
phorescent dye, Pt(II) tetraphenyl-tetranaphthopor-
phyrin [Pt(TPNP)], and surface functionalized with
gadolinium [Gd-Pt(TPNP)] for combined MRI and NIR
optical imaging of head and neck tumors. Studies were
initially carried out in vitro to investigate the optical and
MR properties of the polymeric nanomicelles. Subse-
quently, in vivo studies were carried out using patient
tumor-derived HNSCC xenografts established in nude
mice (Figure 1). The results demonstrate the potential
of Gd-Pt(TPNP) nanomicelles as a dual modality ima-
ging agent for molecular imaging of head and neck
cancers.
Methods
Chemicals
All phospholipids, 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DSPE-mPEG-2000), 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-[amino(polyethylene glycol)-2000]
(DSPE-PEG-2000 NH2), 1,2-distearoylglycero-3-phos-
phocholine (DSPC) and 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-diethylenetriaminepentaacetic
acid (gadolinium salt) (DMPE-Gd) were procured from
Avanti Polar Lipids (Alabaster, AL). All other solvents
were procured from Sigma-Aldrich, (St. Louis, MO) and
were used without any further purification.
Tumor model system
We have recently described the procedures for establish-
ment of primary patient tumor-derived HNSCC xeno-
grafts in SCID mice [6]. Using similar procedures,
tumors were established in athymic nude mice. Female
a t h y m i cn u d em i c e( nu/nu, body weight 22-30 g) were
obtained from Harlan Sprague Dawley, Inc. (Indianapo-
lis, IN) and housed in microisolator cages on-site at the
Figure 1 Schematic of overall study design. The figure depicts
the basic workflow algorithm involved in the design, synthesis and
characterization of the nanoparticles for dual modality imaging.
Following initial synthesis, characterization of the optical properties
of Pt(TPNP)-Gd polymeric nanomicelles was performed using
transmission electron microscopy, optical spectroscopy and dynamic
light scattering techniques. MR relaxometric measurements were
also performed in phantoms and compared to clinically approved
MR contrast agents. Subsequently, in vivo studies were performed
using patient tumor-derived human head and neck squamous cell
carcinoma (HNSCC) xenografts to determine the potential of the
polymeric nanomicelles for dual modality imaging.
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Resource. The mice were provided standard chow/water,
and maintained on 12-hour light/dark cycles in a HEPA-
filtered environment. All procedures were performed in
accordance with protocols approved by the Institutional
Animal Care and Use Committee at Roswell Park Can-
cer Institute.
Synthesis of Pt(TPNP)/Gd nanomicelles
We have recently described the procedure for synthesis
of nanomicelles encapsulating the phosphorescent dye,
Pt(II)-tetraphenyltetranaphthoporphyrin [Pt(TPNP)] in
the hydrophobic core of the DSPE-PEG/DSPC nanomi-
celles [7]. We have modified the reported procedure to
incorporate DMPE-Gd into nanomicelles. A schematic
describing the encapsulation of the Pt(TPNP) into the
DSPE-PEG/DSPC/DMPE-Gd phospholipid micelles is
shown in Figure 2. Briefly, 100 μL of phosphorescent
dye stock solution in toluene (0.12 mg/ml) was evapo-
rated and dried under vacuum. The obtained solid mass
was then resuspended in 1 mL chloroform with 6.33 ×
10
-6 moles of phospholipids containing 17% of DSPE-
mPEG-2000, 17% of DSPE-PEG-2000 NH2,1 3 %o f
DMPE-Gd and 53% of DSPC. The solution was
sonicated for 1 minute and the chloroform allowed to
evaporate under vacuum, following which the residue
was gently heated at 80°C and 2 mL of water was added
to obtain an optically clear suspension containing Pt
(TPNP)/DSPE-PEG/DSPC/DMPE-Gd (from here on
referred as Pt(TPNP)-Gd nanomicelles). Dye/micelle for-
mulation was purified by ultracentrifugation at 500,000
g for 2 hours. The supernatant was discarded and the
pellet containing phosphorescent dye-micelles was
resuspended in water. Samples of Pt(TPNP)-Gd nanomi-
celle formulation were stable in deionized water or
phosphate buffered saline (PBS), with no observable
aggregation, dissociation or bleaching for at least
1 month of storage. The samples were stored at 4°C for
further use.
Characterization of Pt(TPNP)-Gd nanomicelles
The mean diameter of Pt(TPNP)-Gd polymeric micelles
was evaluated by dynamic light scattering (DLS) measure-
ments using a model 90 plus Zeta Sizer (Brookhaven Inc.,
Brookhaven, NY). Transmission electron microscopy was
also performed using a JEOL model JEM-100CX electron
microscope operating at an acceleration voltage of 80 kV.
To measure the morphology and size distribution of
A
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Figure 2 Synthesis and characterization Pt(TPNP)-Gd nanomicelles. (A) Synthesis of phospholipid nanomicelles encapsulating Pt(TPNP) and
surface functionalized with gadolinium, (B) absorption and emission spectra of the micelles, (C) TEM analysis of the nanoparticles showing a
nearly spherical morphology, and, (D) dynamic light scattering analysis showing a unimodal distribution of nanoparticle size (103.6 ± 1.8 nm).
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was placed on a 300-mesh copper grid coated with car-
bon. Approximately 2 minutes after deposition, the grid
was tapped with filter paper to remove surface water and
air-dried. Negative staining was performed using a dro-
plet of 2% wt aqueous phospotungistic aciduranyl acetate.
The optical absorption measurements were done using a
Shimadzu model 3600 UV-Vis-NIR spectrophotometer.
A SPEX 270M spectrometer (Jobin Yvon), equipped with
an InGaAs TE-cooled photodiode (Electro-Optical Sys-
tems, Inc.) was used to obtain the photoluminescence
(PL) spectra. A laser diode emitting at 630 nm was used
as the excitation source. The sample in a quartz cuvette
was placed directly in front of the entrance slit of the
spectrometer, and the emission signal was collected at
90° relative to the excitation light.
Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) studies were per-
formed using a 4.7 T/33-cm horizontal bore magnet
(GE NMR Instruments, Fremont, CA) incorporating
AVANCE digital electronics (Bruker Biospec with Para-
Vision 3.0.2; Bruker Medical Inc., Billerica, MA) and a
removable gradient coil insert (G060, Bruker Medical
Inc., Billerica, MA) generating maximum field strength
of 950 mT/m and a custom-designed 35-mm RF trans-
mit-receive coil. In vitro MR relaxometry was performed
in phantoms containing serial dilutions of the nanomi-
celle formulation over a Gd concentration range of
0-100 μM with varying phospholipid:Gd ratios. T1
relaxation rates (R1) were measured using a Fast Ima-
ging with Steady-State Precession (True-FISP) imaging
sequence with the following scan parameters: field of
view (FOV) = 3.20 × 3.20 cm, matrix size = 128 × 128,
TR/TEeff. = 3.0/1.5 ms, NEX = 1, slice thickness = 1.50
mm, TI = 40.0 ms, flip angle = 60° and number of
echoes = 60. R1 values were plotted as a function of
concentration and linear regression analysis was per-
formed to estimate T1-relaxivities. Estimates were com-
pared to the clinically-approved gadolinium-based
contrast agent, gadopentetate dimeglumine (Gd-DTPA;
Magnevist®).
In vivo MRI studies were performed using nude mice
bearing subcutaneous primary patient tumor-derived
HNSCC xenografts to examine the tumor imaging
potential of the nanoparticles. Images were acquired at
baseline (before nanoparticle injection), immediately
after injection, 4 hours and 24 hours post-administration
of (PtTPNP)-Gd nanoparticles (35 μmol Gd/kg). For
these studies, animals were anesthetized using the inha-
lational anesthetic, Isoflurane (Abbott Laboratories, IL),
induced at 4% in oxygen, and sustained 2-3% during
imaging. The mice were secured in a form-fitted, MR-
compatible sled (Dazai Research Instruments, Toronto,
Canada) equipped with temperature and respiratory
monitoring sensors. The sled, along with a phantom
containing 0.15 mM Magnevist, was then positioned
inside the scanner using a carrier tube composed of cel-
lulose acetate butyrate plastic (Curbell Plastic, Orchard
Park, NY). The animal body temperature was main-
tained at 37°C throughout the scanning process using
an air heater system (SA Instruments Inc., Stony Brook,
NY), and temperature feedback was automatically
initiated due to thermocouples inherent to the sled, in
conjunction with computer software supplied with the
heater. Data acquisition consisted of localizer images
followed by high resolution axial T2-weighted (T2W)
images for anatomic imaging of tumor and normal tis-
sues [FOV = 3.20 × 3.20 cm, matrix size = 256 × 192,
TR/TEeff. = 2500/41.0, NEX = 4, slice thickness = 1.00
mm, interslice distance = 1.25 mm, and number of
echoes = 8]. T1-weighted (T1W) spin echo images were
acquired for examining the tumor enhancement pattern
at different times post nanoparticle injection [FOV =
3.20 × 3.20 cm, matrix size = 256 × 195, TR/TEeff.=
404/7.8 ms, NEX = 4, slice thickness = 1.00 mm, inter-
slice distance = 1.25 mm]. The change in T1-relaxation
rate (R1 = 1/T1) of tumor and kidneys was measured
using a T1-weighted saturation recovery fast spin echo
(T1-FSE) sequence [FOV = 3.20 × 3.20 cm, matrix size
= 128 × 96, NEX = 1, slice thickness = 1.00 mm, inter-
slice distance = 1.25 mm, TEeff = 25 ms and TR = 6000,
3000, 1500, 750, 500, 360.34 ms]. Finally, MR angiogra-
phy was performed using a T1/flow-weighted 3D spoiled
gradient echo (T1-SPGR) sequence with the following
parameters: FOV = 4.80 × 3.20 × 3.20 cm, matrix = 192
×9 6×9 6 ,T R / T E eff.=1 5 . 0 / 3 . 0 ,N E X=1 ,f l i pa n g l e=
40° and slice thickness = 32.00 mm. Image processing
and analysis were carried out using the medical imaging
software ANALYZE (Version 7.0; Biomedical Imaging
Resource, Mayo Foundation, Rochester, MN). Regions
of interest (ROIs) were manually drawn around tumor,
muscle and kidney and object maps were created for
calculation of T1 relaxation rates using MATLAB
(Mathworks Inc., Version 7.1, Natick, MA).
In vivo Optical Imaging
Near-infrared optical imaging of tumor-bearing mice
was performed at the 24 hour time point following com-
pletion of MRI studies. In vivo spectral imaging was car-
ried out using the spectral imaging system, Maestro
GNIR FLEX comprising of an optical head, an optical
coupler and a cooled, scientific-grade monochrome
CCD camera, along with image acquisition and analysis
software. The polymeric micelles were excited at 650-
700 nm using “deep red” excitation filter (CRi), trans-
mitting light from the source (Xe lamp) in the range of
650-700 nm. An emission filter (800 LP) was used to
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tal filter in front of the imaging CCD camera was auto-
matically stepped in 10-nm increments from 800 to 950
nm while the camera captured images at each wave-
length with constant exposure. Overall acquisition time
was about 10 seconds. The 16 resulting TIFF images
were loaded into a single data structure in memory,
forming a spectral stack with a spectrum at every pixel.
Autofluorescence and the Pt(TPNP)-Gd nanomicelles
phosphorescence spectra were obtained from the spec-
tral image using the computer mouse to select appropri-
ate regions. Spectral unmixing algorithms were applied
to create the unmixed images of ‘pure’ autofluorescence
and ‘pure’ phosphorescence signals.
Statistics
All measured values have been reported as mean ± stan-
dard error of the mean. P values less than 0.05 were
considered statistically significant. All statistical calcula-
tions and analyses were performed using Graph Pad
Prism (Version 5.00; Graph Pad, San Diego, CA). A
two-tailed paired student’s t test was used to compare
tumor T1 relaxation rates at various time points in com-
parison to baseline pretreatment values.
Results
Synthesis and characterization of (PtTPNP)-Gd
nanoparticles
A schematic of the workflow involved in the design, synth-
esis and characterization (in vitro and in vivo)o fd u a lm o d -
ality (PtTPNP)-Gd nanoparticles is shown in Figure 1.
Phospholipid nanomicelles encapsulating Pt(TPNP) were
synthesized with gadolinium-functionalized surface as
shown in Figure 2A. As one can see from the absorption
and emission spectra of the micelles presented in Figure
2B, incorporation of DMPE-Gd to the nanomicellar formu-
lation does not significantly affect the basic photophysical
properties of Pt(TPNP) encapsulated in the hydrophobic
core of the nanomicelles (7), and the Pt(TPNP)-Gd nano-
micelles are phosphorescent. TEM analysis revealed a
nearly spherical morphology of the nanoparticles with a
narrow size distribution (Figure 2C). Zeta potential studies
carried out with the Pt(TPNP)-Gd nanomicelles have
shown an overall negative zeta potential owing to the pre-
sence of the PEG molecules on the surface of the nanomi-
celles. The net surface charge of the nanomicelles was
found to be -38.24 mV. Consistent with the TEM observa-
tions, the DLS analysis of the nanoparticles revealed a
unimodal distribution with the maximum percentage
intensity to be of 103.6 ± 1.8 nm in size (Figure 2D).
In vivo MR-NIR optical imaging of HNSCC xenografts
Prior to in vivo investigation, studies were carried out
in vitro to investigate the MR properties of the
gadolinium containing nanomicelles. The T1 relaxivity
of Pt(TPNP)-Gd nanomicellar formulation at 4.7T was
markedly higher (10.4 mmol
-1*s
-1) than the clinically
approved contrast agent, Gd-DTPA (3.6 mmol
-1*s
-1).
Subsequently, inv i v oimaging experiments were carried
out using nude mice bearing primary patient tumor-
derived human HNSCC xenografts. T1-enhancement
characteristics and relaxation rate measurements of
tumor and blood (kidneys) were performed before (pre-
contrast) as well as 1, 4 and 24 hours after nanoparticle
administration (35 μmol Gd/kg). Figure 3 shows color-
ized T1-relaxation maps (R1 maps) calculated from T1-
weighted images of a mouse before (pre), immediately
after (post), 4 hours and 24 hours after injection of the
Pt(TPNP)-Gd nanomicelles. An axial slice showing the
kidneys (upper panel)a n dt h et u m o r( middle panel)i s
shown. An enlarged ROI of the tumor is also shown in
the bottom panel. Signal enhancement was visible
immediately after nanoparticle injection and persisted
up to 24 hours post administration. Measurement of T1
relaxation rates (R1 = 1/T1) showed a significant
increase (P < 0.05 at immediately post and 4 h post
injection; P < 0.01 at 24 h) in tumor R1 at all 3 time
points post nanoparticle administration, compared to
preinjection values with peak enhancement in the tumor
at 4 hours post injection (Figure 4A). A significant
increase in the R1 of the kidneys was also observed
immediately after injection and at 4 h post injection
(Figure 4B, P < 0.001). Maximum intensity projection
(MIP) images generated from 3D T1-weighted images
acquired post contrast showed visible enhancement in
contrast within the tumor and blood vessels in mice
(Figure 4C).
NIR optical imaging, performed following the com-
pletion of MRI at the 24 hour time point, revealed
high contrast phosphorescence signal and confirmed
tumor localization of the nanoparticles (Figure 5A).
The large spectral separation between the Pt(TPNP)
absorption (~700 nm) and phosphorescence emission
(~900 nm) allowed for a dramatic decrease in the level
of background autofluorescence and scattered excita-
tion light. Consistent with previous observations (7),
ex-vivo NIR optical imaging revealed accumulation of
nanoparticles in liver tissues, in addition to tumor
localization (Figure 5A). No significant phosphores-
cence signal was seen from other dissected organs
(heart, spleen, kidneys). Histologic evaluation of liver
tissues did not show any evidence of toxicity following
nanoparticle administration. Figure 5B shows haema-
toxylin and eosin stained liver section obtained from
an animal 48 h following injection of Pt(TPNP)Gd
nanomicelles. No visible change in the histologic archi-
tecture of the liver or evidence of necrosis, fibrosis,
fatty changes or clear cell changes were seen in treated
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tion of an untreated control animal is also shown in
Figure 5B.
Toxicologic evaluation of Pt(TPNP) nanoparticles was
also performed by measuring the body weight of animals
over a 2 week period. Animals injected with Pt(TPNP)
formulation underwent physical and neurological evalua-
tions. No changes in eating, drinking, grooming,
exploratory behavior, activity, physical features (e.g.,
weight and skin color), and neurological status were
observed in animals injected with the nanoformulation
compared to control animals. No significant differences
in average body weight were observed between control
and treatment groups.
Discussion
A tremendous amount of scientific effort has been
placed in recent years towards the generation of multi-
functional nanoparticles for early detection of cancer,
targeted drug delivery to tumors and for monitoring of
cancer therapy. Nanomedicine has the ability to over-
come the limitations of traditional imaging and thera-
peutic agents and to potentially integrate diagnostic and
therapeutic applications in oncology [3-5]. Functionali-
zation of nanocarriers with tumor-targeting moieties
provides the ability to selectively deliver anticancer
agents at optimal concentrations to tumor sites [5]. In
addition, the inclusion of imaging agents enables real
time, non-invasive assessment of tumor physiology, drug
delivery and therapeutic response [3-5].
The objective of the present study was to develop and
characterize a nanoparticle-based platform for dual
modality imaging of HNSCC. Here we report the utility
of phospholipid-PEG based polymeric nanomicelles
encapsulating a NIR phosphorescent dye, and surface
conjugated with gadolinium, as an imaging probe for
combined MRI and optical imaging. Our results demon-
strate that Pt(TPNP)-Gd nanomicelles exhibit a high
degree of tumor-avidity and favorable imaging proper-
ties that allowed for combined MRI and optical imaging
of head and neck tumors.
The polymeric nanoplatform utilized in our study pro-
vides several benefits over conventional imaging agents
which include prolonged circulation time, improved
tumor selective targeting and reduced antigenicity. The
nanomicelles are made of biocompatible copolymers
and exploit the EPR effect commonly observed in
tumors making them ideal carriers for delivery of antic-
ancer drugs, fluorophores and biomolecules selectively
to tumors [8,9]. Several preclinical studies have pre-
viously demonstrated the usefulness of polymeric
micelles as drug carriers [8,9]. A number of polymeric
Figure 3 Magnetic resonance imaging of patient tumor-derived HNSCC xenografts using Pt(TPNP)-Gd nanomicelles.T h ep a n e lo f
images represent T1-relaxation maps calculated before (pre), immediately after (post) and 4 hours and 24 hours post intravenous injection of Pt
(TPNP)-Gd nanomicelles. Axial slices of the kidneys (top panel, white dotted outline) and the tumor (middle panel) are shown. An enlarged view
of the tumor is shown in the bottom panel. Signal enhancement was visible immediately after nanoparticle injection and persisted up to 24
hours post administration.
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are also currently being evaluated in clinical trials [9].
To minimize opsonization, the surface of the nanoparti-
cles was conjugated with polyethylene glycol (PEG), a
relatively inert hydrophilic polymer that provides good
steric hindrance for preventing protein binding. The net
negative charge on the surface of the Pt(TPNP)-Gd
nanomicelles should have a pronounced effect on the
adsorption of different physiological lipoproteins in sys-
temic circulation, playing a critical role in the clearance
of the nanoparticles from the body [10].
The development of a dual modality imaging agent for
combined MRI and optical imaging is attractive, given
the complementary nature of these two imaging modal-
ities. Optical imaging methods provide a high degree of
sensitivity for bioimaging and are relatively inexpensive
and easy to use. Traditionally, clinical application of
optical imaging has been limited by tissue penetration of
visible light. The use of NIR probes for in vivo imaging
allows for imaging of deeper tissues and reduces the
background autofluorescence, providing higher contrast
[8,11], but does not fully overcome the drawback of
optical imaging related to limited depth of light propa-
gation in biological tissues. In contrast to optical ima-
ging methods, MRI suffers from limited sensitivity and
lacks resolution for imaging at the cellular level, but
does not have limitation of depth and provides excellent
soft tissue contrast. Thus, a nanoplatform that allows
for combined MR-NIR imaging could potentially bridge
the gaps in sensitivity/resolution and depth of imaging.
Indeed, such nanoparticle based approaches for com-
bined MR-optical imaging of tumors has been previously
reported [12-14]. These approaches have typically uti-
lized NIR fluorescent dyes, e.g., Cy5.5, in combination
with iron oxide or gadolinium for MR contrast.
PAMAM-dendrimer based nanoparticles and gadoli-
nium-labeled photoluminescent quantum dots have
been examined for their potential for targeted molecular
imaging of lymph nodes and tumor vasculature [12-16].
Dual modality MR-optical imaging approaches have also
been utilized for sentinel lymph node mapping in mice
[16]. Optical tracers have also been studied for diagnos-
tic and therapeutic applications in head and neck can-
cers [17,18].
We have previously demonstrated that phospholipid-
based NIR phosphorescent polymeric nanomicelles exhi-
bit superior optical imaging properties in vivo [7]. In the
same study, using histologic analyses we have shown
that Pt(TPNP) nanomicelles can be safely administered
to animals without any associated short-term toxicities.
The in vitro and in vivo results from the present study
demonstrate the potential of Gd-labeled phosphorescent
nanomicelles as MR contrast agents (Figure 3A, 4A and
4B). Although Gd
3+ based agents (Gd-DTPA; Gd-
DOTA) have been approved for clinical use and are rou-
tinely used in human studies, these agents are associated
with considerable limitations. A majority of the clinically
approved low molecular weight contrast agents are non-
specific in nature and do not contain any targeting moi-
eties. Due to their non-targeted nature, these contrast
agents undergo rapid extravasation and plasma clear-
ance (in the order of minutes) resulting in a very narrow
imaging window. In this regard, the development of ‘tar-
geted’ MR contrast agents associated with longer tissue
retention times would offer a broader imaging window
in which high-resolution images can be acquired. Sec-
ondly, the most commonly used Gd-containing com-
pounds have relatively low relaxivities and can be toxic.
In particular, at high concentrations of the Gd-contain-
ing MRI contrast agents, a significant amount of Gd
3+
ions are released and circulate in a free, uncomplexed
state. These free Gd
3+ ions have been shown to result in
severe toxicities leading to nephrogenic systemic fibrosis
B A
C
Precontrast Postcontrast
Figure 4 MR angiography (MRA) and NIR optical imaging of
HNSCC xenografts using Pt(TPNP)-Gd nanomicelles.
Measurement of T1 relaxation rates of tumor (A) and mouse kidneys
(B) before and at different times after administration of Pt(TPNP)-Gd
nanomicelles. A significant increase in R1 was seen in both tumor
and kidneys after administration of nanomicelles compared to
preinjection estimates. Peak enhancement in the tumor was
observed at 4 hours post injection. (C) Maximum intensity
projections generated from 3D T1-weighted images acquired post
contrast showed visible enhancement in contrast within the tumor,
liver and blood vessels.
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results of our in vitro MR relaxometry studies showed
that Gd-containing polymeric nanomicelles exhibit
superior MR properties (higher T1 relaxivity) compared
to clinically approved Gd-based contrast agents (e.g.,
Gd-DTPA). The higher relaxivity of Gd-containing
nanomicelle formulations could therefore potentially
allow reduction in the amount of injected dose of con-
trast agent, without compromising image contrast. The
combination of optical and MR imaging probes also
facilitated tracking of the biodistribution and tumor
accumulation of the nanoparticles over time.
With increasing interest in the development of novel
targeted therapies for management of head and neck
cancers, nanomedicine is likely to play a significant role
in the diagnostic evaluation, therapy and tumor
response assessment to such targeted therapies in
patients [20].
Conclusions
In conclusion, Pt(TPNP)-Gd polymeric nanomicelles
reported here serve as efficient probes for dual modality
imaging of head and neck tumors in mice. While the
mechanisms involved are not entirely clear, the tumor
specificity is believed to arise from the combination of
the EPR effect and the inherent tumor-avidity of the
phosphorescent platinum-porphyrin complex entrapped
within the nanomicelles [21]. Further investigation into
the potential of Pt(TPNP)-Gd nanomicelles for com-
bined imaging and therapy of head and neck cancers is
necessary and is currently underway.
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